Patient Compliance During PegIntron [peginterferon alfa-2b] (Injection Pen) and Rebetol [ribavirin] Combination Therapy in Chronic Hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 16 Dec 2013
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Schering-Plough
- 31 Aug 2018 Biomarkers information updated
- 10 Oct 2011 Actual patient number is 294 according to ClinicalTrials.gov.
- 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.